ABL Bio stock price, funding rounds, valuation and financials

ABL Bio has raised $90.8 m in total funding. ABL Bio annual revenue was ₩8.1 b in FY 2020

₩568 M

ABL Bio Revenue Q3, 2021
ABL Bio Gross profit (Q3, 2021)575 M
ABL Bio Net income (Q3, 2021)-10 B
ABL Bio EBITDA (Q3, 2021)-10.8 B
ABL Bio EBIT (Q3, 2021)-11.3 B
ABL Bio Cash, 30-Sept-202133.2 B
Get notified regarding key financial metrics and revenue changes at ABL BioLearn more
Banner background

ABL Bio Funding

Summary Metrics

Founding Date

2016

ABL Bio total Funding

$90.8 m

ABL Bio latest funding size

$65 m

Time since last funding

4 years ago

ABL Bio investors

ABL Bio's latest funding round in June 2018 was reported to be $65 m. In total, ABL Bio has raised $90.8 m

ABL Bio Capital Raised

Embed Graph

ABL Bio Revenue Breakdown

Embed Graph

ABL Bio revenue breakdown by business segment: 100.0% from APPAREL MISCELLANEOUS

ABL Bio Income Statement

Annual

KRWFY, 2018FY, 2019FY, 2020

Revenue

1.3b4.0b8.1b

Gross profit

1.6b4.8b16.8b

R&D expense

(31.2b)(52.8b)

Operating expense total

(25.3b)(44.4b)(65.7b)

Depreciation and amortization

(2.1b)

EBITDA

(23.7b)(39.6b)(48.9b)

EBIT

(23.8b)(39.8b)(55.6b)

Interest expense

(93.3b)(90.7m)(72.8m)

Interest income

145.7m1.4b368.2m

Pre tax profit

(117.2b)(37.0b)(55.6b)

Net Income

(117.2b)(37.0b)(55.6b)

Quarterly

KRWQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

872.2m1.1b872.2m1.8b2.3b568.0m

Gross profit

1.1b5.4b5.1b1.8b3.4b575.0m

R&D expense

(14.1b)(16.0b)(12.6b)(9.8b)(9.9b)(8.7b)

Operating expense total

(17.1b)(18.9b)(16.0b)(11.5b)(14.7b)(11.4b)

Depreciation and amortization

(471.6m)(492.7m)(547.4m)(555.7m)(544.4m)(522.2m)

EBITDA

(16.0b)(13.5b)(10.9b)(9.7b)(11.2b)(10.8b)

EBIT

(17.8b)(13.9b)(12.1b)(11.5b)(10.5b)(11.3b)

Interest expense

(19.2m)(18.2m)(16.6m)(14.2m)(11.8m)(9.2m)

Interest income

130.0m117.6m87.8m33.9m21.0m54.5m

Pre tax profit

(14.8b)(14.3b)(12.7b)(8.9b)(8.0b)(10.0b)

Net Income

(14.8b)(14.3b)(12.7b)(8.9b)(8.0b)(10.0b)

ABL Bio Balance Sheet

Annual

KRWFY, 2018FY, 2019FY, 2020

Cash

122.0b91.1b40.7b

Accounts Receivable

5.3b435.2m

Prepaid Expenses

491.5m927.0m334.7m

Current Assets

161.1b134.7b71.9b

PP&E

2.7b5.0b4.1b

Total Assets

168.9b142.9b99.9b

Short-term debt

801.4m940.3m

Current Liabilities

11.6b9.3b8.0b

Long-term debt

555.3m

Non-Current Liabilities

320.7m1.6b1.3b

Total Debt

801.4m1.5b

Total Liabilities

11.9b10.9b9.2b

Common Stock

22.3b22.7b23.1b

Additional Paid-in Capital

332.9b334.4b342.5b

Retained Earnings

(205.7b)(243.3b)(299.1b)

Total Equity

157.0b132.0b90.7b

Quarterly

KRWQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

69.5b77.2b50.1b36.2b24.0b33.2b

Accounts Receivable

110.0m110.0m453.4m

Prepaid Expenses

386.9m122.2m169.8m233.6m48.6m109.5m

Current Assets

125.9b118.9b103.6b69.0b63.1b56.1b

PP&E

4.7b4.7b4.5b3.6b3.3b2.8b

Total Assets

133.8b126.9b111.4b94.5b85.2b76.5b

Short-term debt

796.8m902.4m929.4m933.0m895.7m693.0m

Current Liabilities

9.9b14.0b8.0b7.5b4.9b4.2b

Long-term debt

896.4m905.2m778.8m334.1m108.5m

Non-Current Liabilities

1.6b1.8b2.0b1.2b1.3b1.6b

Total Debt

1.7b1.8b1.7b1.3b895.7m801.4m

Total Liabilities

11.5b15.8b10.0b8.7b6.2b5.8b

Common Stock

23.1b23.1b23.1b23.6b23.6b23.6b

Additional Paid-in Capital

342.5b342.5b342.5b348.7b348.7b348.7b

Retained Earnings

(258.1b)(272.4b)(285.1b)(307.9b)(316.0b)(325.9b)

Total Equity

122.3b111.1b101.5b85.8b79.0b70.7b

ABL Bio Cash Flow

Annual

KRWFY, 2018FY, 2019FY, 2020

Net Income

(117.2b)(37.0b)(55.6b)

Depreciation and Amortization

2.1b

Accounts Receivable

(5.6b)1.1b(2.1b)

Cash From Operating Activities

(12.7b)(23.9b)(47.3b)

Cash From Investing Activities

(22.8b)(8.3b)(3.6b)

Cash From Financing Activities

155.6b(47.5m)598.3m

Net Change in Cash

120.0b(30.9b)(50.5b)

Quarterly

KRWQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(14.8b)(29.1b)(41.8b)(8.9b)(16.9b)(26.9b)

Depreciation and Amortization

471.6m964.3m1.5b555.7m1.1b1.6b

Accounts Receivable

77.6m(1.9b)(1.2b)498.7m1.4b1.6b

Cash From Operating Activities

(11.8b)(24.1b)(40.7b)(8.6b)(19.2b)(28.3b)

Cash From Investing Activities

(14.1b)6.7b(2.9b)2.1b1.3b19.2b

Long-term Borrowings

(209.0m)(414.1m)(645.0m)(486.5m)(725.6m)

Cash From Financing Activities

1.3b1.1b839.3m998.8m757.0m518.0m

Net Change in Cash

(21.7b)(14.0b)(41.1b)(4.5b)(16.7b)(7.5b)

ABL Bio Ratios

KRWFY, 2018